NKGen Biotech, Inc.

Graf Acquisition Corp. IV, trading under the ticker GFOR, is a blank-check company sponsored by Graf Industrial Partners and led by James Graf, who has a track record of prior SPAC formations. The company completed its initial public offering in 2021, targeting the life sciences and healthcare sector. The amended quarterly filing on Form 10-Q/A, submitted January 31, 2022 under accession number 0001410578-22-000068, reflects a restatement period during which the SPAC was actively pursuing a business combination target. Graf Acquisition Corp. IV subsequently announced a definitive merger agreement with NKGen Biotech, Inc., a clinical-stage biopharmaceutical company focused on natural killer cell therapies. Sign up on SpacDesk for full filing history, timeline data, and sponsor analytics on GFOR and hundreds of other SPACs.